RP6530
Showing 1 - 11 of 11
Hematological Malignancies Trial in Georgia, Poland, United States (Tenalisib)
Enrolling by invitation
- Hematological Malignancies
-
San Francisco, California
- +6 more
Nov 1, 2021
Locally Advanced Breast Cancer, Metastatic Breast Cancer Trial in Batumi, Tbilisi (Tenalisib)
Active, not recruiting
- Locally Advanced Breast Cancer
- Metastatic Breast Cancer
-
Batumi, Georgia
- +2 more
May 2, 2022
Leukemia, Lymphocytic, Chronic, B-Cell Trial in Bulgaria, Georgia, Poland (Tenalisib)
Completed
- Leukemia, Lymphocytic, Chronic, B-Cell
-
Pleven, Bulgaria
- +5 more
Jul 22, 2021
Peripheral T Cell Lymphoma Trial in Houston (Tenalisib)
Not yet recruiting
- Peripheral T Cell Lymphoma
-
Houston, TexasThe University of Texas MD Anderson Cancer Center
Aug 17, 2022
Classical Hodgkin Lymphoma Trial in Chicago, Detroit, Seattle (Tenalisib, Pembrolizumab)
Terminated
- Classical Hodgkin Lymphoma
- Tenalisib
- Pembrolizumab
-
Chicago, Illinois
- +2 more
Dec 24, 2019
Lymphoma, Non-Hodgkin Trial in Worldwide (Copanlisib (BAY80-6946), Placebo, Rituximab)
Active, not recruiting
- Lymphoma, Non-Hodgkin
- Copanlisib (BAY80-6946)
- +7 more
-
Chandler, Arizona
- +200 more
Aug 17, 2022
Lymphoma, B-Cell, T-Cell Lymphoma Trial in Paris, Milano (RP6530)
Completed
- Lymphoma, B-Cell
- T-Cell Lymphoma
- RP6530
-
Paris, France
- +2 more
Jun 23, 2016
Leukaemia, Myelocytic, Acute Trial in Australia, Canada, United States (GSK2879552, ATRA)
Terminated
- Leukaemia, Myelocytic, Acute
-
Augusta, Georgia
- +7 more
Apr 2, 2019